Directors' Report and
Unaudited Financial Statements
for the Year Ended 31 December 2018

Company Number: 01073169

MONDAY



A40

30/09/2019 COMPANIES HOUSE

#5

# Contents of the Financial Statements for the year ended 31 December 2018

	Page
Company Information	1
Directors' Report	2
Balance Sheet and Income Statement	
Notes to the Financial Statements	4

# Company Information for the year ended 31 December 2018

Directors:

B Deluard P E Parry E Schmidt

Registered office:

Bampton Road Harold Hill Romford Essex RM3 8UG

Registered number:

01073169

# Directors' Report for the year ended 31 December 2018

The directors present their report with the financial statements of the company for the year ended 31 December 2018.

#### **Directors**

P Parry has held office during the whole of the period from 1 January 2018 to the date of this report.

Other changes in directors holding office are as follows:

B Deluard and E Schmidt were appointed as directors on 11 March 2019.

M Harris ceased to be a director on 1 January 2019.

R Joannesse ceased to be a director on 11 March 2019.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

On behalf of the board:

P E Parry - Director

Date:

27th Sept 2019

# MARTINDALE PHARMACEUTICALS LIMITED (REGISTERED NUMBER: 02581060)

## Balance Sheet 31 December 2018

Total assets less current liabilities	Notes	£	2018 £ 	£	2017 £
Capital and reserves Called up share capital Retained Earnings			100 (100)	-	100 (100)
Shareholders' funds		:	<u>-</u>	=	<u>-</u>

The company is entitled to exemption from audit under section 480 or the Companies Act 2006 for the year ended 31 December 2018.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2018 in accordance with section 476 of the Companies Act 2006.

The directors acknowledge:

- a) Ensuring the company keeps accounting records which company with Sections 386 and 387 of the Companies Act 2006 and
- b) Preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and its profit of loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to the financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors on 25th Se.pt 20 on its behalf by:

25th Se pt 2019 and were signed

P E Parry - Director

## Income Statement For the year ended 31 December 2018

During the financial year and the preceding financial year, the company has not traded and has received no income and incurred no expenditure. Consequently, during those periods the company has made neither a surplus nor a deficit.

### **AURUM PHARMACEUTICALS LIMITED**

# Notes to the Financial Statements for the year ended 31 December 2018

#### 1. Statutory information

Martindale Pharmaceuticals Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

### 2. Accounting policies

#### Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

#### 3. Ultimate controlling party.

The ultimate parent undertaking is Financière Verdi III, a company incorporated in France.

Financière Verdi III prepares group financial statements and copies can be obtained from:

Financière Verdi III 194, Bureaux de la Colline 92213 Saint-Cloud – FRANCE

#### 4. Contingent liabilities

The Company has guaranteed bank and other borrowings of a parent undertaking, Orphea Limited, amounting to £55 million (2017: £55 million).